---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-010301"
form_type: "8-K"
ticker: "CBIO"
cik: "0001253689"
company_name: "CRESCENT BIOPHARMA, INC."
filed_at: "2023-05-22T23:59:59+00:00"
generated_at: "2026-06-14T18:01:16.184750+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# GlycoMimetics stockholders elect all director nominees, ratify auditor, approve say-on-pay

## Summary
- Three director nominees elected: Andrews (36.2M for, 0.5M withheld), Goldberg (32.6M/4.0M), Pearson (36.3M/0.4M); 14.2M broker non-votes.
- Ratification of Ernst & Young as auditor approved: 50.3M for, 0.5M against, 0.05M abstained.
- Advisory vote on executive compensation approved: 36.1M for, 0.4M against, 0.1M abstained; 14.2M broker non-votes.
- Approximately 79% of outstanding shares (50.9M of 64.2M) represented at the meeting.

## SEC filing metadata
- accession: 0001558370-23-010301
- form_type: 8-K
- ticker: CBIO
- cik: 0001253689
- company_name: CRESCENT BIOPHARMA, INC.
- filed_at: 2023-05-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1253689/000155837023010301/0001558370-23-010301-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1253689/000155837023010301/glyc-20230519x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-010301
- JSON: https://secwatch.observer/filing/0001558370-23-010301.json
- Plain text: https://secwatch.observer/filing/0001558370-23-010301.txt

## Key facts
- Shareholder Votes
  CRESCENT BIOPHARMA, INC. shareholders approved To approve, on an advisory basis, the executive compensation of the Company's named executive officers as disclosed in the proxy materials. at the 2023-05-19 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-05-19
  source text: Proposal No. 3: To approve, on an advisory basis, the executive compensation of the Company's named executive officers as disclosed in the proxy materials. The votes were cast as follows: ​ Votes For Votes Against Abstained Approved, on an advisory basis, the executive compensation. 36,116,823 ​ 435,570 ​ 112,283 ​ Broker Non-Votes: 14,198,293.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837023010301/0001558370-23-010301-index.htm
- Shareholder Votes
  CRESCENT BIOPHARMA, INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-05-19 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-05-19
  source text: Proposal No. 2 : Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. The votes were cast as follows: ​ Votes For Votes Against Abstained Ratification of appointment of Ernst & Young 50,337,103 ​ 474,059 ​ 51,807
  evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837023010301/0001558370-23-010301-index.htm
- Shareholder Votes
  CRESCENT BIOPHARMA, INC. shareholders approved Election of three nominees to serve as directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified. at the 2023-05-19 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-05-19
  source text: Proposal No. 1 : Election of three nominees to serve as directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: ​ Name Votes For Votes Withheld Patricia Andrews 36,190,925 ​ 473,751 Mark Goldberg, M.D. ​ 32,642,583 ​ 4,022,093 Timothy Pearson ​ 36,279,306 ​ 385,370 ​ ​ Broker Non-Votes: 14,198,293. ​ All nominees were elected.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837023010301/0001558370-23-010301-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.